Retatrutide, a innovative dual-acting glucose-dependent incretin analog, represents a significant advance in peptide medicines for the management of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor activator, offering